XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer

The epidermal growth factor receptor (EGFR) and the insulin-like growth factor-1 receptor (IGF-1R) play critical roles in tumor growth, providing a strong rationale for the combined inhibition of IGF-1R and EGFR signaling in cancer therapy. We describe the design, affinity maturation, in vitro and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Schanzer, Juergen M., Wartha, Katharina, Moessner, Ekkehard, Hosse, Ralf J., Moser, Samuel, Croasdale, Rebecca, Trochanowska, Halina, Shao, Cuiying, Wang, Peng, Shi, Lei, Weinzierl, Tina, Rieder, Natascha, Bacac, Marina, Ries, Carola H., Kettenberger, Hubert, Schlothauer, Tilman, Friess, Thomas, Umana, Pablo, Klein, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966845/
https://www.ncbi.nlm.nih.gov/pubmed/26984378
http://dx.doi.org/10.1080/19420862.2016.1160989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966845/
https://www.ncbi.nlm.nih.gov/pubmed/26984378
http://dx.doi.org/10.1080/19420862.2016.1160989

Ejemplares similares